In a patient with recurrent fibrolamellar HCC a year after upfront resection (previously refused adjuvant therapy) with a solitary abdominal mass, would you offer neoadjuvant therapy to assess response?

Or offer resection followed by adjuvant therapy?

Answer from: Medical Oncologist at Academic Institution

Recurrent disease is the best care for under clinical trials for FLC. There are not many, sadly because of limited support. But there are some, like NCT03860272.

Answer from: at Community Practice

We (FibroFighters Foundation, www.fibrofighters.org - a non-profit dedicated to FLC have seen more FLC than anyone in the world - in the last year alone - approximately 140 cases) would recommend systemic therapy for any FLC patient with very few exceptions (the only exceptions: stage 1, &...

Please select the option that best describes you:

In a patient with recurrent fibrolamellar HCC a year after upfront resection (previously refused adjuvant therapy) with a solitary abdominal mass, would you offer neoadjuvant therapy to assess response?

Related Questions